STOCK TITAN

Tempest Therapeutics Inc - TPST STOCK NEWS

Welcome to our dedicated news page for Tempest Therapeutics (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tempest Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tempest Therapeutics's position in the market.

Rhea-AI Summary
TPST - Tempest Therapeutics, Inc. reports superior results for TPST-1120 in liver cancer study, strengthening balance sheet. Multiple study endpoints showed promising results, including a 30% confirmed objective response rate and a median progression-free survival of 7 months for TPST-1120 arm. The company also plans to advance TPST-1120 into a registrational study and reported positive financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
-
Rhea-AI Summary
Tempest Therapeutics adopts limited duration stockholder rights plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics announces positive results from a Phase 1b/2 study of TPST-1120 in combination with atezolizumab + bevacizumab in the treatment of hepatocellular carcinoma (HCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
none
Rhea-AI Summary
Tempest Therapeutics to report new data from Phase 1b/2 combination study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
conferences
-
Rhea-AI Summary
Tempest Therapeutics announces expansion of role for executive VP and CMO, Sam Whiting, to include head of Research and Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
Rhea-AI Summary
Tempest Therapeutics, Inc. reported financial results for Q2 2023, including positive data from their TPST-1120 and TPST-1495 clinical programs. TPST-1120 demonstrated a 74.4% relative improvement in objective response rate (ORR) and a 69.9% relative improvement in confirmed ORR. TPST-1495 showed increased potency against prostaglandin-driven tumor models. The company expects to discuss updated data from the TPST-1120 trial in H2 2023 and report data from the TPST-1495 combination arm in 2024. Tempest ended Q2 with $17.6 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
-
Rhea-AI Summary
Tempest Therapeutics announces publication of in vitro and in vivo data on TPST-1495, a novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling. The data shows increased potency compared to existing drugs and supports previous clinical results of tumor shrinkage and disease control. Tempest also highlights their innovative pipeline, including TPST-1120 for first-line HCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
conferences
Rhea-AI Summary
Tempest Therapeutics announces Phase 1 clinical trial data for TPST-1495 to be presented at ASCO Annual Meeting. Data shows tumor shrinkage and prolonged disease control in both monotherapy and combination with pembrolizumab. Treatment well tolerated with manageable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.76%
Tags
conferences clinical trial
Tempest Therapeutics Inc

Nasdaq:TPST

TPST Rankings

TPST Stock Data

79.67M
17.77M
3.16%
29.33%
4.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Ann Arbor

About TPST

tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.